Killed it with puts today!
They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.
Operating Margin (ttm) -905.50%
Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%
Revenue Per Share $0.30
News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr...
Find out more https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-appoints-daniel-b-soland-to-board-of-directors-8035190.html
News: $KALV KalVista Pharmaceuticals to Present at Needham Healthcare Conference
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...
Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-to-present-at-needham-healthcare-conference-7939130.html
News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...
Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-7846828.html
CBYL is now KALV with a 1:14 reverse stock split.
Be very careful for the next few days as until all or most of the CBYL shares are converted to KALV, the only sellers will be private Kal Vista investors, those who bought after the symbol change and professionals. The price is likely to be high until existing CBYL retail holders can sell their shares. In addition, the existing CBYL shares will only represent 20% of the O/S. 80% will be held by the private investors in KVAL.
Oh okay. Im still up for it even if it is a merger. Good thing volume picked up today.
New buyer? They're not being bought, they're merging with another company and selling their cash at a steep discount.
Maybe the large shareholders decided it's better to take a smaller loss now by liquidating, than wait for a larger loss later and they're voting against the deal.
I can only hope!
Fun while it lasted.
Sadly, I don't think so.
LOL, CBYL declined back to $0.49 again! The next two supports are $0.4505 and $0.4401.
Let' see if that very sick merger deal still goes through...
Anyway the planned big Reverse/Split (1:14) should kick in very soon unless we all vote against it!
Can you please stick that post#376 to the CBYL board? Thanks in advance! We all should call the company and let them merge with TNXP to protect our interests in CBYL! It will be the best deal for both Debt-Free and High BV & CV Bio-Tech NASDAQ companies!
Anyway CBYL is up 5.6% so far! $0.4984 seems the New bottom support! Hopefully it will test last week's highs area $0.544 ~ $0.54 again before the end of today...
Now CBYL has Three strong supporting price $0.4401, $0.4505, and $0.475!
Who are those very stupid sellers which put 88K shares at $0.60 and over 130K shares at $0.65?
Get him on the phone NOW!
A New Merger proposal to the CEO of CBYL! TNXP is the best merger candidate for CBYL since both companies have Zero-Debt and High Positive Book Value & Cash Value plus TNXP has two FDA-Approved New Drugs (Phase3 and Phase2 respectively)! It is called "Stronger Together Merger"...
In this way the combined company will have very strong cash flow and very strong financial strength without any debt at all plus the two very promised New drugs with FDA-Approval!
Should this deal kick in both public stocks will be doubled within a single day! This is the best solution for both companies and their shareholders! TNXP may take 70% ownership v.s. CBYL take the rest 30% ownership...
CBYL declined to $0.4984 so far from yesterday's high $0.545! Let's see if the price will test $0.475 or even $0.4505 again during the rest of today...
I wish $0.46 ~ $0.47 could hold the New bottom support for this round of price correction so that CBYL can easily test $0.57 ~ $0.545 again!
Anyway the 52-week low is $0.4401 which was created a couple of weeks ago without any bad news at all except the terrible aged reverse-merger deal --- see the link below for the details.
KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need. KalVista has built an expanding clinical and advanced preclinical product pipeline targeting multiple routes of administration to treat these diseases.
KalVista’s initial focus is on advancing a portfolio of orally delivered plasma kallikrein inhibitors for the treatment of HAE. The most advanced program, KVD818, is in Phase I clinical studies and additional molecules are expected to reach the clinic in 2017. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 clinical studies.
KalVista has an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.
KalVista has offices in Cambridge, MA, USA and Salisbury, UK.